Kyowa Kirin已将其中国业务单元出售给香港WinHealth Pharma Group。此举是Kyowa Kirin优化其亚太地区运营战略的一部分。此次转让包括Kyowa Kirin中国制药有限公司及其在中国的五个已建立品牌，转让价格最高可达人民币7.2亿元（约合150亿日元或1亿美元)。

此外，Kyowa Kirin已与WinHealth签订了推广和分销协议，授予其全球产品CRYSViTA®和POTELIGEO®的商业权利。

Kyowa Kirin决定将其中国业务单元出售给香港WinHealth Pharma Group是其优化亚太地区运营的更广泛战略的一部分。以下是对Kyowa Kirin在中国业务的一些关键影响：

专注核心领域：Kyowa Kirin将集中资源于其核心疾病领域，如骨和矿物质疾病、难治性血液疾病和罕见疾病。此战略重点旨在增强公司的增长和创新能力。

战略合作伙伴关系：通过与WinHealth合作，Kyowa Kirin确保其在中国的已建立品牌继续得到有效推广和分销。此合作伙伴关系使Kyowa Kirin能够利用WinHealth的本地专业知识和市场影响力。

可持续运营：此次出售是Kyowa Kirin 2030愿景目标的一部分，包括创建更可持续和盈利的运营。此重组预计将帮助Kyowa Kirin保持其药品的患者可及性，同时保障员工的未来。

财务影响：最高可达人民币7.2亿元（约合150亿日元）的转让价格为Kyowa Kirin提供了可观的财务资源，这些资源可以再投资于其核心业务领域和未来的增长计划。

总体而言，此举旨在简化Kyowa Kirin的运营，专注于高增长领域，并确保亚太地区的长期可持续性和盈利能力。

图片来源｜协和麒麟网站

协和麒麟上海生产基地成立于1997年，是“国家上海生物医药科技产业基地”成立后引进的第一个生物高科技医药项目，建有药品生产车间、仓库、仪器分析实验室、无菌实验室、动物实验室、办公楼及设备楼等。

2023年10月，上海生产基地扩建项目正式竣工并投入使用，主要用于新引进的生物药品注射剂的扩产和提高产品的仓储能力，以便尽快实现新产品上市，满足公众用药需求。

• 引入全自动立体仓储系统，提升生产过程信息化水平

• 引入智能化系统，提高运作效率及空间利用率，全面提升企业智能化管理水平

• 配套式光伏项目已并网发电，预计每年可减少300吨碳排放

Singapore August 1, 2024

Kyowa Kirin Asia Pacific Pte. Ltd., a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto), announced plans to transform its Asia-Pacific (APAC) business for more sustainable and profitable operations, through strategic partnerships with DKSH Holding Ltd. ("DKSH") and Hong Kong Winhealth Pharma Group (“Winhealth”).

Kyowa Kirin will also focus in-house resources on its future-growth core disease areas of bone and mineral, intractable hematological diseases/ hemato-oncology, and rare diseases by forming its APAC Cluster covering South Korea, Taiwan and Australia markets.

These moves underscore Kyowa Kirin’s Vision 2030 goals of delivering life-changing value to patients in APAC by ensuring continued access to a portfolio of 11 brands across four therapeutic areas such as NESP® for renal anemia and ROMIPLATE® for platelet production.

Under the terms of the agreement with DKSH, Kyowa Kirin has entered into a promotion and distribution agreement with DKSH for commercial rights to Kyowa Kirin’s established medicines portfolio including seven brands in Hong Kong / Macau, South Korea, Malaysia, Singapore, Taiwan and Thailand markets. Additionally, Kyowa Kirin has also signed a promotion and distribution agreement with DKSH for commercial rights to Kyowa Kirin’s global products: CRYSViTA® in Hong Kong / Macau, Malaysia, Singapore and Thailand markets, as well as POTELIGEO® in Singapore.

Under the terms of the agreement with WinHealth, Kyowa Kirin China Pharmaceutical Co., Ltd., including its five established brands in China, will be transferred to a special-purpose company that will inherit them under Winhealth at a transfer price of up to RMB 720 million (approximately JPY 15.0 billion). Additionally, Kyowa Kirin has entered into a promotion and distribution agreement with WinHealth for commercial rights to Kyowa Kirin’s global products (CRYSViTA® and POTELIGEO®).

Abdul Mullick, Ph.D., Chief International Business Officer (CIBO) of Kyowa Kirin said, “Guided by our 'Story for Vision 2030', we have developed a strategy to continue delivering life-changing value and shape the future of Kyowa Kirin. We have defined our focus disease areas and identified opportunities to maximize the value of our products through in-house efforts and strategic partnerships. Recognizing the increasing challenges in the APAC region, we have made the difficult decision to restructure our APAC business, to ensure continued access to our medicines for patients, securing the future for as many of our employees as possible and ensuring sustainability. This transformation will enhance our efficiency and agility, empowering our team to make a great impact on patient lives and make people smile.”